Advertisement

Archives of Gynecology and Obstetrics

, Volume 241, Issue 2, pp 73–85 | Cite as

Contragestion by antiprogestin RU 486: A review

  • E. E. Baulieu
  • A. Ulmann
  • D. Philibert
Review Article

Summary

The steroidal derivative RU 486 (17β-hydroxy-11β-(4-dimethyl-aminopheny 1)-17α-(prop-1-ynyl)-estra-4,9-dien-3-one) is the first potent antiprogestin in medical use. Acting reversibly at the molecular level of receptor binding, RU 486 blocks progesterone action and allows endocrine functions to return quickly to normal after its use. However, target cells dynamics that depend upon a continuity of progesterone action will be irreversibly disrupted. In normal women RU 486 acts during the luteal phase in the endometrium, provoking bleeding, and also decreases LH secretion which results in luteolysis. In pregnant women, if affects the decidual, increases myometrial contractility and ripening of the cervix, and ultimately leads to termination of pregnancy. Detachment of the trophoblast leads to a fall in chronic gonadotrophin. Clinical studies indicate that RU 486 can be a very efficient agent for the termination of early pregnancy, and as a postcoital menstrual regulator. The failures observed when RU 486 is given alone may be overcome by the additional use of oxytocics. A small amount of prostaglandin given at the end of RU 486 treatment gives satisfactory results at up to 8 weeks of amenorrhea. Treatment with RU 486 is short term, and apparently has no significant side-effects despite the compound's antiglucocorticosteroid activity.

Key words

Fertility control Antiprogesterone Steroid receptor Hsp 90 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baulieu EE, Raynaud JP (1970) A “proportion graph” method for measuring binding system. Eur J Biochem 13:293–304PubMedGoogle Scholar
  2. 2.
    Baulieu EE, Schorderet-Slatkine S (1983) Steroid and peptide control mechanisms in membrane resuming meiotic division. In: Porter R Whelan J (eds) Molecular Biology of Egg Maturation—Ciba Foundation Symposium 98. Pitman, Bath, pp 137–158Google Scholar
  3. 3.
    Baulieu EE, Segal SJ (1985) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 1–353Google Scholar
  4. 4.
    Baulieu EE (1987) Steroid hormone antagonists at the receptor level. A role for the heat-shock protein MW 90,000 (hsp 90). J Cell Biochem 24 (in press)Google Scholar
  5. 5.
    Bergstrom S, Diczfalusy E, Borell U, Karim S, Samuelsson B, Uvnas B, Wiqvist N, Bygdeman M (1972) Prostaglandins in fertility control. Science 175:1280–1287Google Scholar
  6. 6.
    Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F (1984) The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59:25–28PubMedGoogle Scholar
  7. 7.
    Binart N, Catelli MG, Geynet C, Puri V, Hahnel R, Mester J, Baulieu EE (1979) Monohydroxytamoxifen: an antiestrogen with high affinity for the chick oviduct estrogen receptor. Biochem Biophys Res Commun 91:812–818PubMedGoogle Scholar
  8. 8.
    Bourgeois S, Pfahl M, Baulieu EE (1984) DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU 486. EMBO J 3:751–755PubMedGoogle Scholar
  9. 9.
    Cabrol D, Bouvier d'Yvoire M, Mermet E, Cedard L, Sureau C, Baulieu EE (1985) Induction of labour with mifepristone after intrauterine fetal death. Lancet II:1019Google Scholar
  10. 10.
    Cameron IT, Michie AF, Baird DT (1986) Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (Gemeprost). Contraception 34:459–468PubMedGoogle Scholar
  11. 11.
    Catelli MG, Binart N, Jung-Testas I, Renoir JM, Baulieu EE, Feramisco, JR, Welch WJ (1985) The 90-kd protein of non-transformed “8S” steroid receptors is a heat-shock protein. EMBO J 4:3131–3135PubMedGoogle Scholar
  12. 12.
    Cook RJ (1985) Legal abortion: limits and contributions to human life. In: Porter R, O'Connor M (eds) Abortion: medical progress and social implications. Ciba Foundation Symposium 115. Pitman, London, pp 211–227Google Scholar
  13. 13.
    Couzinet B, Le Strat N, Ulmann A, Baulieu EE Schaison G (1986) Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). New Engl J Med 315:1565–1570PubMedGoogle Scholar
  14. 14.
    Csapo AI (1979) Antiprogesterone in fertility control. In: Zatuchni GI, Sciarra JJ, Speidel JJ (eds) Pregnancy termination: procedures, safety, and new developments. Harper and Rew, Hagerstown, pp 16–34Google Scholar
  15. 15.
    Csapo AI, Pulkkinen MO, Wiest WG, (1973) Effects of luttectomy and progesterone replacement in early pregnancy patients. Am J Obstet Gynecol 115:759–765PubMedGoogle Scholar
  16. 16.
    Csapo A, Dray F, Erdos T (1975) The biological effects of injected antibodies to estradiol-17β and to progesterone in pregnant rats. Endocrinology 97:603–614PubMedGoogle Scholar
  17. 17.
    Daraedt R, Bonnat C, Busigny M, Chatelet P, Cousty C, Mouren M, Philibert D, Potier J, Salmon J (1985) Pharmacokinetics of RU 486. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 103–122Google Scholar
  18. 18.
    Djerassi C (1970) Birth control after 1984. Science 169:941–951PubMedGoogle Scholar
  19. 19.
    Gaillard RC, Riondel A, Muller MF, Herrmann W, Baulieu EE (1984) RU 486: a steroid with antiglucocorticoisteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 81:3879–3882PubMedGoogle Scholar
  20. 20.
    Gasc JM, Ennis BW, Baulieu EE, Stumpf WE (1983) Recepteur de la progesterone dans l'oviducte de poulet: double revelation par immunohistochimie avec des anticorps antirecepteur et par autoradiographie à l'aide d'un progestagene tritie. C R Acad Sci 297:477–482Google Scholar
  21. 21.
    Gravanis A, Schaison G, George M, De Brux J, Satyaswaroop PG, Baulieu EE, Robel P (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenauposal women. J Clin Endocrinol Metab 60:156–163PubMedGoogle Scholar
  22. 22.
    Groyer A, Le Bouc Y, Joab I, Radanyi C, Renior JM, Robel P, Baulieu EE, (1985) Chick oviduct glucocorticosteroid receptor. Specific binding of RU 486 and immunological studies with antibodies to chick oviduct progesterone receptor. Eur J Biochem 149:445–451PubMedGoogle Scholar
  23. 23.
    Healy DL, Hodgen GD, (1985) Non-human primate studies with RU 486. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 127–140Google Scholar
  24. 24.
    Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE, (1982) Effet steroîde anti-progesterone chez la femme: interruption du cycle menstruel et de la grossesse au debut. C R Acad Sci Paris 294:933–938Google Scholar
  25. 25.
    Herrmann WL, Schindler AM, Wyss R, Bishof P, (1985) Effects of, antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In: Baulieu EE Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 179–198Google Scholar
  26. 26.
    Hospital M, Busetta M, Bucourt R, Weintraub H, Baulieu EE (1972), X-ray crystallography of estrogens and their binding to receptor sites. Mol Pharmacol 8:438–445PubMedGoogle Scholar
  27. 27.
    Joab I, Radanyi C, Renoir JM, Buchou T, Catelli MG, Binart N, Mester J, Baulieu EE (1984) Immunological evidence for a common non hormone-binding component in “non-transformed” chick oviduct receptors of four steroid hormones. Nature 308:850–853PubMedGoogle Scholar
  28. 28.
    Jung I, Baulieu EE (1983) Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor. Exp Cell Res 147:177–182PubMedGoogle Scholar
  29. 29.
    Kelly RW, Healy DL, Cameron MJ, Cameron IT, Baird DT (1986) The stimulation of prostaglandin production by two antiprogesteron steroids in human endometrial cells. J Clin Endocrinol Metab 62:1116–1123PubMedGoogle Scholar
  30. 30.
    Levy C, Robel P, Gautray JP, De Brux J, Verma U, Descomps B, Baulieu EE, Eychenne B (1980) Estradiol and progesterone receptors in human endometrium: normal and abnormal menstrual cycles and early pregnancy. Am J Obstet Gynecol 136:646–651PubMedGoogle Scholar
  31. 31.
    Milgrom, E, Atger M, Baulieu EE, (1970) Progesterone in uterus and plasma. IV-Progesterine receptor(s) in guinea pig uterus cytosol. Steroids 16:741–754PubMedGoogle Scholar
  32. 32.
    Moguilewsky M, Philibert D (1984) RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 20:271–276PubMedGoogle Scholar
  33. 33.
    Nadler RD, Roth-Meyer C, Baulieu EE (1985) Behavioral and endocrine consequences of longterm antiprogesterone (RU 486) administration to Cynologus monkeys: preliminary results. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 169–177Google Scholar
  34. 34.
    Nieman LK, Healy DL Spitz IM, Merriam GR, Bardin CW, Loriaux DL, Chrousos G (1985) Use of single dose of the antiprogesterone steroid RU 486 for induction of menstruation in normal women. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 279–284Google Scholar
  35. 35.
    Birgerson L, Odlind V, Johnsson E (1985) Clinical effects of RU 486 administered for seven days in early pregnancy. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 235–241Google Scholar
  36. 36.
    Philibert D, Moguilewsky M, Mary I, Lecaque D, Tournemine C, Secchi J, Deraedt R (1985) Pharmacological profile of RU 486 in animals. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 49–68Google Scholar
  37. 37.
    Pincus G (1965) The control of fertility. Academic Press, New York, pp 1–360Google Scholar
  38. 38.
    Rauch M, Loosfelt H, Philibert D, Milgrom E (1985) Mechanism of action of an antiprogesterone, RU 486, in the rabbit endometrium. Eur J Biochem 148:213–218PubMedGoogle Scholar
  39. 39.
    Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H (1986) The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial. Bull Cancer (in press)Google Scholar
  40. 40.
    Sakiz E, Euvrard C, Baulieu EE (1984) The antiprogestin activity of RU 486, a contragestive agent in the human. In: Labrie F, Proulx L (eds) Endocrinology. Excerpta Medica, Amsterdam, pp 239–242Google Scholar
  41. 41.
    Schaison G, George M, Le Strat N, Baulieu EE (1985) Effects of the antiprogesterone steroid RU 486 during mid-luteal phase in normal women. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 271–278Google Scholar
  42. 42.
    Segal SJ, Teitze C (1971) Contraceptive technology: current and prospective methods. Rep Popul Fam Plann 1:1–24PubMedGoogle Scholar
  43. 43.
    Segal SJ, Atkinson LE (1973) Systemic contragestional agents. In: Osofsky HJ, Osofsky JD (eds) The abortion experience. Harper and Row, Hagerstown, pp 400–414Google Scholar
  44. 44.
    Smith HE, Smith RG, Toft DO, Neergard JR, Burrows EP, O'Malley BW (1974) Binding of steroids to progesterone receptor proteins in chick oviduct and human uterus. J Biol Chem 249:5924–5932PubMedGoogle Scholar
  45. 45.
    Spitz IM Wade CE, Krieger DT, Kahteenmaki P, Bardin CW (1985) Effect of RU 486 on the pituitary-adrenal axis in the dog. In: Baulieu EE Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 315–330Google Scholar
  46. 46.
    Sutherland RL, Mester J, Baulieu EE (1977) Hormonal regulation of sex steroid hormone receptor concentration and subcellular distribution in chick oviduct. Nature 267:434–435PubMedGoogle Scholar
  47. 47.
    Swahn ML, Cekan S, Wang G, Lundstom V, Bygdeman M (1985) Pharmacokinetic and clinical studies of RU 486 for fertility regulation. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, pp 249–258Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • E. E. Baulieu
    • 1
  • A. Ulmann
    • 2
  • D. Philibert
    • 2
  1. 1.Lab-Hormones, INSERM U 33Université Paris-SudBicêtre
  2. 2.Roussel UclafRomainvilleFrance

Personalised recommendations